406 related articles for article (PubMed ID: 27025860)
21. [Bisphosphonate-associated osteonecrosis of the jaw].
Koy S; Schubert M; Koy J; Ney M; Lauer G; Sabatowski R
Schmerz; 2015 Apr; 29(2):171-8. PubMed ID: 25860198
[TBL] [Abstract][Full Text] [Related]
22. Experience with the treatment of bisphosphonate-related osteonecrosis of the jaw.
Janovska Z; Mottl R; Slezak R
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Jun; 159(2):313-7. PubMed ID: 24108250
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of laser-assisted treatments for medication-related osteonecrosis of the jaw: a systematic review.
Li FL; Wu CB; Sun HJ; Zhou Q
Br J Oral Maxillofac Surg; 2020 Apr; 58(3):256-267. PubMed ID: 31926767
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of guided autofluorescence laser therapy in MRONJ: a systematic review.
Dipalma G; Inchingolo AD; Piras F; Palmieri G; Pede CD; Ciocia AM; Siciliani RA; Olio FD; Inchingolo AM; Palermo A; Inchingolo F; Favia G; Limongelli L
Eur Rev Med Pharmacol Sci; 2023 Dec; 27(24):11817-11831. PubMed ID: 38164845
[TBL] [Abstract][Full Text] [Related]
25. Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients.
Vescovi P; Merigo E; Meleti M; Manfredi M; Guidotti R; Nammour S
J Oral Pathol Med; 2012 Mar; 41(3):214-21. PubMed ID: 21958312
[TBL] [Abstract][Full Text] [Related]
26. Treatment of medication-related osteonecrosis of the jaw (MRONJ). A systematic review.
Goker F; Grecchi E; Grecchi F; Francetti L; Del Fabbro M
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2662-2673. PubMed ID: 33829453
[TBL] [Abstract][Full Text] [Related]
27. Multipotent mesenchymal stromal cell sheet therapy for bisphosphonate-related osteonecrosis of the jaw in a rat model.
Kaibuchi N; Iwata T; Yamato M; Okano T; Ando T
Acta Biomater; 2016 Sep; 42():400-410. PubMed ID: 27326918
[TBL] [Abstract][Full Text] [Related]
28. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
[TBL] [Abstract][Full Text] [Related]
29. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics.
Freiberger JJ; Padilla-Burgos R; McGraw T; Suliman HB; Kraft KH; Stolp BW; Moon RE; Piantadosi CA
J Oral Maxillofac Surg; 2012 Jul; 70(7):1573-83. PubMed ID: 22698292
[TBL] [Abstract][Full Text] [Related]
30. Bisphosphonate-associated osteonecrosis of the jaw.
Ferreira Jr LH; Mendonça Jr KD; Chaves de Souza J; Soares Dos Reis DC; do Carmo Faleiros Veloso Guedes C; de Souza Castro Filice L; Bruzadelli Macedo S; Soares Rocha F
Minerva Dent Oral Sci; 2021 Feb; 70(1):49-57. PubMed ID: 32960522
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant therapies in the management of medication-related osteonecrosis of the jaws: Systematic review.
de Souza Tolentino E; de Castro TF; Michellon FC; Passoni ACC; Ortega LJA; Iwaki LCV; da Silva MC
Head Neck; 2019 Dec; 41(12):4209-4228. PubMed ID: 31502752
[TBL] [Abstract][Full Text] [Related]
32. Accurate approach in the treatment of oral bisphosphonate-related jaw osteonecrosis.
de Souza Faloni AP; Queiroz TP; Comelli Lia RC; Cerri PS; Margonar R; Rastelli AN; Marcantonio E
J Craniofac Surg; 2011 Nov; 22(6):2185-90. PubMed ID: 22075816
[TBL] [Abstract][Full Text] [Related]
33. A preliminary report about treatment of bisphosphonate related osteonecrosis of the jaw with Er:YAG laser ablation.
Stübinger S; Dissmann JP; Pinho NC; Saldamli B; Seitz O; Sader R
Lasers Surg Med; 2009 Jan; 41(1):26-30. PubMed ID: 19143020
[TBL] [Abstract][Full Text] [Related]
34. [Osteonecrosis of the jaw associated with bisphosphonate therapy in primary osteoporosis. Review of the literature].
Outeiriño-Fernández A
An Sist Sanit Navar; 2013; 36(1):87-97. PubMed ID: 23648496
[TBL] [Abstract][Full Text] [Related]
35. Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines.
Patel S; Choyee S; Uyanne J; Nguyen AL; Lee P; Sedghizadeh PP; Kumar SK; Lytle J; Shi S; Le AD
Oral Dis; 2012 Oct; 18(7):625-32. PubMed ID: 22420684
[TBL] [Abstract][Full Text] [Related]
36. Issues with the surgical treatment of antiresorptive agent-related osteonecrosis of the jaws.
Kagami H; Inoue M; Kobayashi A; Taguchi A; Li X; Yoshizawa M
Oral Dis; 2018 Mar; 24(1-2):52-56. PubMed ID: 29480637
[TBL] [Abstract][Full Text] [Related]
37. Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes.
O'Ryan FS; Lo JC
J Oral Maxillofac Surg; 2012 Aug; 70(8):1844-53. PubMed ID: 22595135
[TBL] [Abstract][Full Text] [Related]
38. Nd:YAG laser biostimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: clinical experience in 28 cases.
Vescovi P; Merigo E; Manfredi M; Meleti M; Fornaini C; Bonanini M; Rocca JP; Nammour S
Photomed Laser Surg; 2008 Feb; 26(1):37-46. PubMed ID: 18248160
[TBL] [Abstract][Full Text] [Related]
39. Clinical treatment outcomes for 40 patients with bisphosphonates-related osteonecrosis of the jaws.
Lee LW; Hsiao SH; Chen LK
J Formos Med Assoc; 2014 Mar; 113(3):166-72. PubMed ID: 24630034
[TBL] [Abstract][Full Text] [Related]
40. Systemic administration of quality- and quantity-controlled PBMNCs reduces bisphosphonate-related osteonecrosis of jaw-like lesions in mice.
Kuroshima S; Nakajima K; Sasaki M; I T; Sumita Y; Asahara T; Asahina I; Sawase T
Stem Cell Res Ther; 2019 Jul; 10(1):209. PubMed ID: 31311585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
